The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Chuikyo Wraps Up 1st Round of Discussions on 2020 Medical Fee Revision
The Central Social Insurance Medical Council, better known as Chuikyo, on July 24 wrapped up the “first round” of discussions on the 2020 medical fee revision, which was launched in March, with the health ministry putting together opinions raised so…
To read the full story
Related Article
- Japan Likely to Take Pass on Rewarding Formulary Initiatives under Medical Fee Schedule
January 14, 2020
- Chuikyo Members Oppose Creation of Medical Fees for “Formularies” at Special Function Hospitals
December 16, 2019
- Chuikyo Reps Want Early Debate for 2020 Drug Price Revision; Polypharmacy, Formulary Also on Agenda
March 28, 2019
- Chuikyo Approves Discussion Timeline for FY2020 Reimbursement Reform; Drug Pricing Debates Expected from June
March 7, 2019
REGULATORY
- Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
December 23, 2025
- Japan, Spain Move to Deepen Pharmaceutical Regulatory Cooperation
December 23, 2025
- Japan Drops Transitional Plan for PCV20 Routine Shot in Elderly
December 23, 2025
- Tecartus Now in Line for Orphan Status with Japan Panel Nod
December 23, 2025
- LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
December 22, 2025
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…